Promising combo aims to delay hormone therapy in prostate cancer

NCT ID NCT05893381

Recruiting now Disease control Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 16 times

Summary

This study tests whether adding a targeted radiation drug (Lu-PSMA) to standard stereotactic radiotherapy can better control prostate cancer that has spread to 1-3 small spots. About 70 men with asymptomatic metastases will be randomly assigned to receive either the combination or radiotherapy alone. The goal is to see if the combination delays cancer progression and the need for long-term hormone therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UO Medicina Nucleare, AUSL della Romagna
RECRUITING

Cesena, FC, 47521, Italy

Contact Email: •••••@•••••
UO Medicina Nucleare, IRCCS IRST
RECRUITING

Meldola, FC, 47014, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER